Latest News
Sep 17, 2018

Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ: MYL) ("Mylan") today announced that positive new data from the companies' Phase 3 clinical program for...

Sep 13, 2018

Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Esmolol Hydrochloride in Sodium Chloride Injection, 2,500 mg/250 mL (10 mg/mL) Single-Dose Plastic Bag and...

Sep 11, 2018

Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ: MYL) ("Mylan") today announced that new data from the Phase 3 YUPELRI™ (revefenacin) inhalation...

Sep 5, 2018

We are pleased to confirm that on Aug. 31, 2018, Mylan closed an agreement with Novartis to purchase the worldwide rights to commercialize their global cystic fibrosis products consisting of TOBI...

Aug 13, 2018

Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Tadalafil Tablets USP, 20 mg, the first generic version of the reference listed drug, Eli Lilly and...

View More


Search News Releases

Contact Mylan Communications

Global Communications 
724.514.1968
communications@mylan.com

Stay Connected